Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS

Next Previous
Trial Profile

A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Aspirin; Cyclophosphamide; Dexamethasone; Enoxaparin sodium; Granulocyte colony-stimulating factors; Melphalan; Prednisone
  • Indications Deep vein thrombosis; Multiple myeloma; Myocardial infarction; Pulmonary embolism; Stroke; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms MPRvsMEL200

Most Recent Events

  • 22 Jul 2024 Status changed from active, no longer recruiting to completed.
  • 28 Jun 2023 Planned End Date changed from 1 Jun 2022 to 1 Jun 2025.
  • 17 Jun 2021 Results of meta-analysis of randomized controlled trials (IFM 2009, EMN02/HOVON 95, RV-MM-EMN-441, RV-MM-PI-209 and FORTE), assessing association of HDT-AHCT with PFS in newly diagnosed high-risk myeloma, with overall survival being the secondary objective, presented at the 26th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top